Poseida Therapeutics, Inc. Common Stock
PSTX
PSTX was delisted on the 7th of January, 2025.
94 hedge funds and large institutions have $78.4M invested in Poseida Therapeutics, Inc. Common Stock in 2023 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 35 increasing their positions, 17 reducing their positions, and 34 closing their positions.
388% more call options, than puts
Call options by funds: $195K | Put options by funds: $40K
106% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 17
7% less funds holding
Funds holding: 101 → 94 (-7)
21% less first-time investments, than exits
New positions opened: 27 | Existing positions closed: 34
42% less capital invested
Capital invested by funds: $136M → $78.4M (-$57.6M)
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$8.42M |
| 2 |
State Street
Boston,
Massachusetts
|
+$2.26M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.84M |
| 4 |
William Blair & Company
Chicago,
Illinois
|
+$1.37M |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$1.04M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$5.04M |
| 2 |
PBA
Paradigm Biocapital Advisors
New York
|
-$3.3M |
| 3 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$3.08M |
| 4 |
LCM
Laurion Capital Management
New York
|
-$1.68M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.56M |
PSTX Hedge Fund Activity: Q2 2023 in Review
94 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in Poseida Therapeutics, Inc. Common Stock (PSTX) for Q2 2023, worth a combined $78.4M — down 42% from $136M a quarter earlier.
Sellers outnumbered buyers: 34 funds closed out of PSTX and 27 opened new positions — a net loss of 7 holders — while 17 trimmed existing stakes and 35 added.
The largest buyer was BlackRock, adding an estimated $8.42M. The largest seller was EcoR1 Capital, cutting an estimated $5.04M.
- 94 institutional investors held Poseida Therapeutics, Inc. Common Stock (PSTX) as of Q2 2023, down from 101 in Q1 2023.
- Funds reported $78.4M of Poseida Therapeutics, Inc. Common Stock stock for Q2 2023, down 42% quarter-over-quarter.
- 27 funds opened new Poseida Therapeutics, Inc. Common Stock positions in Q2 2023 and 34 closed out, a net change of -7 holders.
- The largest Poseida Therapeutics, Inc. Common Stock buyer in Q2 2023 was BlackRock, an estimated $8.42M added.
- The largest Poseida Therapeutics, Inc. Common Stock seller in Q2 2023 was EcoR1 Capital, an estimated $5.04M sold.
Based on aggregated 13F filings for Q2 2023.